<DOC>
	<DOCNO>NCT02675114</DOCNO>
	<brief_summary>To establish safety effectiveness Edwards SAPIEN 3 Transcatheter Heart Valve patient severe , calcific aortic stenosis low operative risk standard aortic valve replacement ( AVR ) .</brief_summary>
	<brief_title>The PARTNER 3 - Trial - The Safety Effectiveness SAPIEN 3 Transcatheter Heart Valve Low Risk Patients With Aortic Stenosis</brief_title>
	<detailed_description>Prospective , randomize , control , multi-center trial . Patients operative mortality &lt; 2 % ( low operative risk ) surgical aortic valve replacement randomize 1:1 receive either transcatheter heart valve replacement ( TAVR ) Edwards SAPIEN 3 aortic valve replacement commercially available surgical bioprosthetic valve . Patients see follow-up visit discharge , 30 day , 6 month , annually 10 year .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . No age restriction . 2 . Severe , calcific aortic stenosis . 3 . Heart team agree patient risk operative mortality STS &lt; 4 . 4 . The study patient inform nature study , agree provision provide write informed consent approve Institutional Review Board ( IRB ) respective clinical site . 1 . Iliofemoral vessel characteristic would preclude safe placement introducer sheath . 2 . Evidence acute myocardial infarction â‰¤ 1 month ( 30 day ) randomization . 3 . Aortic valve congenital unicuspid congenital bicuspid valve , noncalcified . 4 . Severe aortic regurgitation ( &gt; 3+ ) . 5 . Severe mitral regurgitation ( &gt; 3+ ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sapien 3</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>heart disease</keyword>
	<keyword>aortic stenosis</keyword>
	<keyword>SAVR</keyword>
	<keyword>TAVR</keyword>
</DOC>